Clinical Trial Update: A Study of the Efficacy and Safety of ICA-17043 (With or Without Hydroxyurea) in Patients With Sickle Cell Anemia. [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the efficacy and safety of ICA-17043 (senicapoc), with or without hydroxyurea, in patients with sickle cell disease and sickle cell ane…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• ICA-17043 (senicapoc)

Snippet

Sponsor: Icagen | Conditions: Sickle Cell Disease, Sickle Cell Anemia | Phase 2 | Status: COMPLETED